Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

10 clinical studies listed.

Filters:

Testosterone Deficiency

Tundra lists 10 Testosterone Deficiency clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07500766

Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Introduction: Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil. Objective: To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism. Methods: This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction. Outcomes: The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence. Clinical Significance: This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction. Relevance and Impact: This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-03-30

Male Hypogonadism
Testosterone Deficiency
Testosterone Replacement Therapy
+1
NOT YET RECRUITING

NCT07476222

PREDICTORS OF TESTOSTERONE DECLINE IN MIDDLE-AGED MEN

Age-related decline in testosterone levels in men is associated with multiple metabolic, functional and psychosocial consequences. Early identification of modifiable factors associated with decreased testosterone levels may contribute to improved prevention of androgen deficiency and related health conditions. This population-based observational cross-sectional study aims to investigate morphometric, functional and lifestyle factors associated with decreased total testosterone levels in middle-aged men. Approximately 650-800 men aged 35-55 years residing in the Andijan region of Uzbekistan will be recruited. Participants will undergo comprehensive assessment including anthropometric measurements, functional performance tests, standardized questionnaires evaluating lifestyle factors and laboratory determination of serum total testosterone levels. Morphometric variables will include body mass index, waist circumference, hip circumference and waist-to-hip ratio. Functional status will be assessed using hand-grip strength, chair-stand test, balance assessment and the six-minute walk test. Lifestyle factors including physical activity, sleep habits, dietary patterns and harmful habits will be evaluated using validated questionnaires. The study aims to identify predictors of decreased testosterone levels and develop a predictive model for early identification of androgen deficiency in middle-aged men.

Gender: MALE

Ages: 35 Years - 55 Years

Updated: 2026-03-20

Testosterone Deficiency
Androgen Deficiency
Male Hypogonadism
NOT YET RECRUITING

NCT07408440

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.

Gender: FEMALE

Ages: 40 Years - 65 Years

Updated: 2026-02-17

1 state

Menopause
Sexual Dysfunction
Libido Disorder
+1
RECRUITING

NCT06343870

Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

Estrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effective to treat symptoms secondary to estrogen and androgen deficiencies and minimize these adverse events. This study evaluates the efficiency of subdermal implant-bioabsorbable use in women with menopausal symptoms associated with secondary estrogen and androgen deficiencies in women with natural menopause, premature ovarian failure or surgical menopause due to cervical cancer. Pharmacokinetic, biochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as the effects on quality of life, menopausal symptoms and sexual function after treatment.

Gender: FEMALE

Ages: 18 Years - 60 Years

Updated: 2025-12-29

1 state

Menopause
Testosterone Deficiency
Estrogen Deficiency
RECRUITING

NCT07227740

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

Heart attacks and strokes are among the most common causes of premature death in individuals living with spinal cord injury (SCI) and appear to occur earlier in life. The factors that lead to the heighten and accelerated risk of heart attacks and strokes in adults living with SCI remain poorly understood. The investigators aim to uncover why this happens and find ways to prevent it. Our research focuses on how important cells which line blood vessels, called endothelial cells, function after SCI. The investigators test endothelial function in live conscious people with SCI. The investigators also study signaling molecules endothelial cells release called endothelial cell derived microvesicles (EMVs), which the investigators can measure in blood to tell us the health of endothelial cells. By using these rigorous tests of vascular function, the investigators have determined that endothelial cells appear dysfunctional after SCI. The investigators also know that many men with SCI have low testosterone levels. Our team has studied testosterone's effects on endothelial dysfunction and believe low testosterone may be contributing to endothelial dysfunction after SCI. By understanding these mechanisms, the investigators hope to improve the lives of those living with SCI and reduce their risk for heart attacks and strokes. The investigators propose to study the influence of testosterone on endothelial function by using state-of-the-art clinical and laboratory experiments to assess endothelial function in men with SCI with low and normal testosterone levels.

Gender: MALE

Ages: 18 Years - 89 Years

Updated: 2025-11-21

1 state

Spinal Cord Injuries
Endothelial Dysfunction
Testosterone Deficiency
NOT YET RECRUITING

NCT04601233

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samples and a rectal exam in volunteers 55 years and older.

Gender: MALE

Ages: 18 Years - Any

Updated: 2025-08-29

1 state

Multiple Sclerosis
Erectile Dysfunction
Testosterone Deficiency
RECRUITING

NCT04460872

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.

Gender: MALE

Ages: 18 Years - Any

Updated: 2025-05-06

1 state

Spinal Cord Injury
Spinal Cord Injuries
Trauma, Nervous System
+17
RECRUITING

NCT04833426

Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy

Sexual dysfunction is a common side effect of radical prostatectomy (RP) and has a significant negative impact on quality of life. With age the testosterone level in men declines; around 30% of men over 70 years of age meet the criteria of testosterone deficiency (TD). The negative impact of both TD and RP on sexual performance are likely to add up. The aim of this study is to assess the efficacy and safety of testosterone replacement therapy (TRT) on functional and oncological outcomes in testosterone deficient men following RP for prostate cancer (PCa).

Gender: MALE

Ages: 18 Years - Any

Updated: 2025-05-02

Prostatic Neoplasms
Hypogonadism
Testosterone Deficiency
RECRUITING

NCT06841328

Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes

This study investigates the safety and efficacy of stem cell or stem cell-derived exosome therapy for gonadal failure, including testicular failure, hypogonadism, ovarian insufficiency, and premature ovarian failure (POF). Conducted at First IVF Clinic, Dubai, it will include 60 participants (30 males, 30 females) aged 20-50 years who have not responded to conventional treatments such as HRT, TRT, or ART. Participants will receive intra-gonadal (testicular or ovarian) injections of stem cells or exosomes, with follow-ups at 3, 6, 9, and 12 months to monitor hormonal changes, gonadal function, and potential adverse effects. The study aims to determine whether regenerative therapy can restore hormone production, enhance reproductive function, and regenerate gonadal tissue, providing a novel, culturally appropriate fertility treatment in the UAE, where donor sperm and eggs are not permitted. By bridging the gap between preclinical research and clinical application, this study could offer new hope to individuals with gonadal failure, advancing the field of regenerative reproductive medicine.

Gender: All

Ages: 20 Years - 50 Years

Updated: 2025-04-10

1 state

Gonadal Dysfunction
Gonadal Failure
Azoospermia
+3
ACTIVE NOT RECRUITING

NCT06794346

Sexual Effects of Transdermal or Vaginal Testosterone

The aim of the study is to elucidate the role of testosterone treatment in postmenopausal women's sexual function and their therapeutic safety.

Gender: FEMALE

Ages: 38 Years - 60 Years

Updated: 2025-01-27

1 state

Female Sexual Dysfunction
Postmenopausal Symptoms
Testosterone Deficiency
+1